Core Viewpoint - The company aims to enhance the efficiency of idle raised funds by investing up to 25 million yuan in high-security, liquid financial products, ensuring the safety of the principal investment and not affecting the construction of fundraising projects [2] Group 1 - The company announced on December 22 that it plans to use idle raised funds for investment [2] - The maximum amount for investment is set at 25 million yuan [2] - The investment will be in financial products that are high in security and liquidity [2] Group 2 - The investment period will not exceed 12 months [2] - The investment is valid for 12 months from the date of approval by the company's board of directors [2] - The funds can be used in a rolling manner within the specified limit [2]

Core Viewpoint - The company, Jiangsu Lude Medical Electronics Co., Ltd., is focused on innovation in technology and lean manufacturing, aiming to build a comprehensive family health ecosystem through a dual-driven strategy of "medical devices + health management" [1][2]. Group 1: Shareholder Activity - The company's major shareholder, Dong Shixiang, has reduced his holdings by 2.48 million shares, representing a decrease of 1.4212%, with a total reduction amounting to 23.92 million yuan, leaving him with 7.7584 million shares, which is 4.4461% of the total shares [1]. Group 2: Product and Market Strategy - The company has developed a complete industrial chain from product research and development to global sales, focusing on home medical devices and health care products, including cardiovascular monitoring and respiratory therapy [1]. - The company is actively engaged in the "smart elderly care + home health care" sector, providing health management solutions for the elderly through smart wearable devices that monitor vital signs [2]. - Sales are primarily concentrated in overseas markets, utilizing an ODM model and establishing strong partnerships with local brands through participation in international medical device exhibitions [2]. - The company is expanding its reach through cross-border e-commerce platforms like Amazon and Alibaba, directly accessing end consumers [2]. Group 3: Operational Efficiency - The company is implementing lean management practices to optimize production line layouts and improve capacity utilization, thereby enhancing production efficiency [2]. - It prioritizes resource allocation for important clients and short delivery cycle orders to ensure product delivery capabilities [2]. - The construction of the Lude Medical Health Industrial Park is underway, with the first phase expected to be completed next year, aimed at improving R&D efficiency and reducing innovation costs [2]. Group 4: Marketing and R&D - The company is actively participating in industry exhibitions and client visits to expand its customer base and strengthen communication with major clients [3]. - There has been a year-on-year increase in new foreign trade customers and sales through cross-border e-commerce platforms [3]. - The company continues to enhance its product innovation and accelerate product registration and certification, with a focus on new applications for nebulization [3]. - As of June 2025, the company holds 113 authorized patents, including 9 invention patents, providing substantial technical support for its ongoing operations [3]. Group 5: Financial Performance - In the first three quarters of 2025, the company achieved operating revenue of 216 million yuan and a net profit attributable to shareholders of 17.69 million yuan [4].

Core Viewpoint - The stock of Lude Medical (920278) experienced a significant decline of 10.97% on December 19, 2025, closing at 10.71 yuan, with a total market capitalization of 1.869 billion yuan [1] Group 1: Stock Performance - On the trading day, the stock opened at 11.4 yuan, reached a high of 11.5 yuan, and a low of 10.45 yuan, with a trading volume of 2.78 billion yuan and a turnover rate of 34.51% [1] Group 2: Shareholder Actions - Shareholder Xiang Guoqiang completed a share reduction plan, selling 2,480,000 shares, which represents 1.4212% of the total share capital, between October 10, 2025, and December 17, 2025 [1] - The reduction occurred at a price range of 8.60 to 10.50 yuan per share, totaling 23,922,358.18 yuan [1] - After the reduction, Xiang Guoqiang holds 7,758,400 shares, accounting for 4.4461% of the total shares [1] - The combined shareholding of the actual controller and concerted parties is 54.8468% [1]

Group 1 - The core point of the article is that Xiang Guoqiang, a major shareholder and actual controller of Lude Medical, plans to reduce his shareholding by selling 2.48 million shares between October 10, 2025, and December 17, 2025, for approximately 23.92 million yuan, with a selling price range of 8.6 to 10.5 yuan per share [1] - After the reduction, Xiang Guoqiang will hold about 7.76 million shares, representing approximately 4.45% of the company's total shares [1]

Group 1 - The stock of Lude Medical (920278) experienced a decline of 10.97% with a turnover rate of 34.51% and a trading volume of 278 million yuan, indicating significant market activity [2][3] - The net selling amount from brokerage seats totaled 26.1969 million yuan, reflecting a bearish sentiment among investors [2][3] - The top five brokerage seats accounted for a total transaction volume of 62.9289 million yuan, with buying transactions amounting to 18.3660 million yuan and selling transactions reaching 44.5629 million yuan [3] Group 2 - The largest buying brokerage was Guotai Junan Securities Co., Ltd. with a purchase amount of 3.5120 million yuan, while the largest selling brokerage was Guojin Securities Co., Ltd. with a selling amount of 13.9406 million yuan [3] - Detailed trading data shows that multiple brokerage seats participated in both buying and selling, with significant selling pressure observed from various firms [3]

具体来看，今日上榜营业部中，第一大买入营业部为国金证券股份有限公司深圳分公司，买入金额为 1392.84万元，第一大卖出营业部为国金证券股份有限公司成都武成大街证券营业部，卖出金额为 1812.64万元。（数据宝） 鹿得医疗12月18日交易公开信息 鹿得医疗（920278）今日上涨18.52%，全天换手率42.92%，成交额3.63亿元，振幅32.72%。龙虎榜数据 显示，营业部席位合计净卖出2170.06万元。 北交所公开信息显示，当日该股因日价格振幅达32.72%、日换手率达42.92%上榜，营业部席位合计净 卖出2170.06万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.06亿元，其中，买入成交额为4194.14 万元，卖出成交额为6364.20万元，合计净卖出2170.06万元。 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 国金证券股份有限公司深圳分公司 | 1392.84 | 579.97 | | 买二 | 国泰海通证券股份有限公司云南昆明人民中路营业部 | 708.06 | ...

每经讯，2025年12月18日，北交所上市公司鹿得医疗（920278，收盘价：12.03元）登上龙虎榜，交易方式是连续竞价，披露原 因是当日价格振幅达到32.72%，成交数量3178.22万股，成交金额3.63亿元。买一席位为国金证券股份有限公司深圳分公司，买 入1392.84万元；卖一席位为国金证券股份有限公司成都武成大街证券营业部，卖出1812.64万元。 | | 2025-12-18鹿得医疗 (920278) 龙虎榜 | | | | --- | --- | --- | --- | | 序号 | 交易营业部名称 | 买入金额(元) | 卖出金额(元) | | | 国金证券股份有限公司深圳分公司 | 13928383.57 | 5799749.53 | | | 国泰海通证券股份有限公司云南昆明人民中路营业部 | 7080622.65 | 53542 | | | 国盛证券有限责任公司河南分公司 | 6544221.95 | 0 | | | 银泰证券有限责任公司淄博华光路证券营业部 | 6476881.88 | O | | | 东吴证券股份有限公司上海西藏南路证券营业部 | 5438582.46 | 11366 ...

从资金流向上来看，当日医疗器械板块主力资金净流入3995.21万元，游资资金净流出1.07亿元，散户资 金净流入6660.68万元。医疗器械板块个股资金流向见下表： 证券之星消息，12月18日医疗器械板块较上一交易日上涨0.42%，鹿得医疗领涨。当日上证指数报收于 3876.37，上涨0.16%。深证成指报收于13053.98，下跌1.29%。医疗器械板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 ...

证券之星消息，12月17日医疗器械板块较上一交易日上涨1.08%，鹿得医疗领涨。当日上证指数报收于 3870.28，上涨1.19%。深证成指报收于13224.51，上涨2.4%。医疗器械板块个股涨跌见下表： 从资金流向上来看，当日医疗器械板块主力资金净流出1.02亿元，游资资金净流出482.75万元，散户资 金净流入1.07亿元。医疗器械板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 ...

截至2025年12月2日收盘，鹿得医疗（920278）报收于9.08元，较前一交易日下跌1.52%，最新总市值为 15.84亿元。该股当日开盘9.27元，最高9.27元，最低9.05元，成交额达718.6万元，换手率为1.07%。 公司近日发布公告称，股东朱文军因减持计划实施完毕，通过集中竞价方式减持公司股份1,000,000股， 占公司总股本的0.5731%，减持期间为2025年9月5日至2025年12月1日，减持价格区间为9.09-12.00元/ 股，已减持总金额为11,390,892.62元。本次减持与此前披露的计划一致，减持后朱文军持股数量为 5,432,000股，持股比例由3.6860%下降至3.1129%。 最新公告列表 《江苏鹿得医疗电子股份有限公司股东减持股份结果公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...